CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) has announced the appointment of Dr. Michael R. Charlton as Senior Vice President of Clinical Development, effective October 1, 2024. This key addition is set to bolster the company’s efforts in advancing its research and development in nonalcoholic steatohepatitis (NASH).
Dr. Charlton brings over 30 years of expertise in hepatology, gastroenterology, and liver transplantation, with a focus on NASH. His distinguished career includes leadership roles at the Mayo Clinic and the University of Chicago, where he directed innovative clinical programs addressing liver diseases. With more than 200 publications to his name, Dr. Charlton has also contributed to the formulation of NASH management guidelines for the American Association for the Study of Liver Diseases.
Becky Taub, M.D., Chief Medical Officer and President of Research & Development at Madrigal, expressed her enthusiasm about the new appointment. “I am thrilled to have Dr. Charlton joining the Madrigal team; his deep experience as a researcher and clinician treating patients with NASH will bring powerful new insights and capabilities to Madrigal as we shape the next phase of our R&D strategy.”
Bill Sibold, CEO of Madrigal, highlighted the significance of Dr. Charlton’s role in the company’s ongoing commitment to NASH innovation. “Madrigal has established the most advanced and comprehensive clinical development program in NASH, and the appointment of Dr. Charlton reflects our commitment to continue innovating for patients. As a prominent global thought leader in the field, he will provide important strategic perspective to Madrigal and expand our partnerships with the hepatology community.”
Dr. Charlton expressed his excitement about joining Madrigal at this pivotal time. “I am excited to begin a new chapter of my career at Madrigal, a company at the forefront of innovation in NASH R&D,” he said. “After 15 years of research and clinical development, Madrigal has energized the NASH field with a breakthrough therapy in Rezdiffra (resmetirom), and I believe this is just the beginning. I look forward to collaborating with my colleagues at Madrigal and our many partners in the hepatology community to drive new advances in care for patients with this serious disease.”
With Dr. Charlton’s extensive experience, Madrigal Pharmaceuticals is well-positioned to further its NASH research and deliver breakthrough therapies to patients globally.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.